Research Use Only - Not for human consumption. 18+ only.
Clinical TrialsPain & AnalgesiaSubcutaneous

Enkephalins (Met-Enkephalin, Leu-Enkephalin)

Also known as: Met-Enk, Leu-Enk, Endogenous opioid peptides

Endogenous opioid peptides that modulate pain perception and mood through mu and delta opioid receptors. Researched as alternatives to traditional opioids.

Research Status

Clinical Trials

Clinical trials

For research purposes only. Not approved for human use. Not medical advice.

Research Areas

Modulates pain perception through opioid receptors
Influences mood and emotional regulation
May reduce anxiety and stress responses
Supports natural pain management pathways
Research model for opioid receptor function

Side Effects

Respiratory depression
UncommonSerious

Opioid agonists can suppress respiratory drive, particularly at higher doses or with repeated administration. Monitor respiratory rate and oxygen saturation. Seek immediate medical attention if breathing becomes shallow or labored. Risk increases with concurrent CNS depressants.

Nausea and vomiting
CommonMild

Opioid-induced nausea occurs in 20-30% of users, often resolving within days as tolerance develops. Take with food or ginger supplements. Antiemetics (ondansetron) may be used if severe.

Constipation
CommonMild

Opioids reduce GI motility. Increase fluid intake, dietary fiber, and physical activity. Stool softeners or osmotic laxatives (polyethylene glycol) are effective preventive measures.

Dizziness and lightheadedness
CommonMild

Opioids can cause orthostatic hypotension and CNS effects. Rise slowly from sitting or lying positions. Avoid driving or operating machinery until effects are understood.

Pruritus (itching)
UncommonMild

Opioid-induced itching is mediated by mast cell degranulation and histamine release. Antihistamines (cetirizine, diphenhydramine) or low-dose naloxone may provide relief.

Euphoria or dysphoria
UncommonMild

Opioid effects on mood are variable and dose-dependent. Some users experience mild euphoria; others may experience dysphoria or emotional blunting. Monitor mood changes and report significant changes to a healthcare provider.

Tolerance development
CommonModerate

Repeated opioid exposure leads to receptor desensitization and reduced efficacy. Tolerance typically develops over days to weeks. Dose escalation may be necessary, but increases risk of adverse effects and dependence.

Physical dependence
UncommonModerate

Chronic opioid use can produce physical dependence, characterized by withdrawal symptoms (anxiety, insomnia, muscle aches, sweating) upon discontinuation. Taper gradually under medical supervision to minimize withdrawal.

Miosis (pinpoint pupils)
CommonMild

Opioid agonists cause pupil constriction. This is a characteristic sign of opioid activity and is generally benign but may affect vision in low-light conditions.

Local injection site reactions
RareMild

Redness, swelling, or mild discomfort at the injection site. Rotate injection sites to minimize risk. Apply ice if needed. Severe or persistent reactions warrant medical evaluation.

Headache
UncommonMild

Opioids can trigger or worsen headaches in some users. Ensure adequate hydration and consider over-the-counter analgesics if needed.

Seizures
RareSerious

Opioid-induced seizures are rare but documented, particularly at high doses or in susceptible individuals. Seek immediate medical attention if seizure activity occurs. Avoid in patients with seizure history without medical supervision.

Dosing Reference

ParameterValue
Dose range1-10 mcg
Frequency1-2x daily
TimingMorning and/or evening, or as per research protocol
RouteSubcutaneous

Dosage varies significantly depending on research application and route of administration. Start at lower end and titrate based on response. For research purposes only. Intranasal and subcutaneous routes most common in clinical research.

Research disclaimer

Figures drawn from published research literature and community logs. Not clinical recommendations. Consult a qualified professional. Research use only.

Reconstitution Guide

Do not use saline or bacteriostatic saline — use only bacteriostatic water for reconstitution

Do not shake the vial vigorously; gentle swirling prevents peptide degradation

Discard immediately if the solution appears cloudy, discolored, or contains visible particles

Use within 30 days of reconstitution when stored at 2–8°C

Do not freeze the reconstituted solution; freezing may denature the peptide

Use the PeptideVolt reconstitution calculator for your exact concentration

Use the PeptideVolt reconstitution calculator for your exact concentration

Molecular and Pharmacological Data

Molecular weight573.67 Da (Met-Enkephalin); 556.64 Da (Leu-Enkephalin)
Half-life2-5 minutes (plasma); varies by tissue and route of administration
SequenceMet-Enkephalin: YGGFM; Leu-Enkephalin: YGGFL

Enkephalins are endogenous pentapeptides that bind to mu (μ) and delta (δ) opioid receptors in the central and peripheral nervous systems. They modulate pain perception by inhibiting the release of neurotransmitters involved in pain signaling and influence mood, stress response, and emotional regulation through activation of opioid receptor pathways. These peptides represent the body's natural pain-relief and mood-modulating system, making them valuable research models for understanding opioid pharmacology and developing non-addictive pain management alternatives.

Mu (μ) Opioid Receptor Signaling

Enkephalins bind to mu receptors in the spinal cord and brain, inhibiting pain signal transmission and producing analgesia. This pathway also influences mood, reward processing, and stress responses.

Delta (δ) Opioid Receptor Signaling

Delta receptor activation by enkephalins modulates pain perception, emotional responses, and may have neuroprotective effects. Delta signaling is associated with anxiolytic and mood-enhancing effects.

G-Protein Coupled Receptor (GPCR) Cascade

Opioid receptor activation triggers intracellular signaling cascades involving G-proteins, reducing cAMP levels and modulating ion channel activity, leading to decreased neuronal excitability and pain signal suppression.

Descending Pain Inhibition Pathway

Enkephalins activate inhibitory interneurons in the dorsal horn of the spinal cord, suppressing the transmission of nociceptive (pain) signals from peripheral tissues to the brain.

  • Enkephalins are the first identified endogenous opioid peptides, discovered in 1975
  • Met-Enkephalin and Leu-Enkephalin differ only in the C-terminal amino acid (methionine vs. leucine)
  • Both peptides show preferential binding to delta receptors but also activate mu receptors
  • Enkephalins are rapidly degraded by peptidases in plasma and tissues, limiting systemic bioavailability
  • Research focuses on structural modifications to increase stability and receptor selectivity
  • Intranasal and intrathecal routes bypass enzymatic degradation and improve CNS penetration

Track your Enkephalins (Met-Enkephalin, Leu-Enkephalin) research

Free account. No credit card required.

Start Free

Browse the Research Library

40+ peptide profiles with mechanism summaries, dosing data, and reconstitution guides.

View all peptides

Research Use Only. All content on this page is provided for informational and educational purposes related to scientific research. Enkephalins (Met-Enkephalin, Leu-Enkephalin) is not approved for human use by the FDA or any equivalent regulatory body. This is not medical advice. Do not use any substance discussed here for therapeutic, diagnostic, or preventative purposes. Consult a qualified healthcare professional before making any health-related decisions. The Peptide Volt does not endorse the use of any research chemicals. 18+ only.